Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026)
Sarepta Therapeutics' (SRPT) quarterly Gross Margin came in at 85.12% in Q1 2026, up 8829.0% year-on-year from 0.95% in Q1 2025, and up 752.46% quarter-over-quarter from 9.98% in Q4 2025.
Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026) Analysis & Trends
Sarepta Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 85.12% for Q1 2026.
- On a quarterly basis, Gross Margin rose 8829.0% year-over-year to 85.12% in Q1 2026; TTM through Mar 2026 was 62.88%, a 1208.0% decrease from a year earlier, with the FY2025 full-year figure at 54.96%, down 2826.0% from the prior year.
- Gross Margin climbed to 85.12% in Q1 2026 per SRPT's latest filing, from 9.98% in the prior quarter.
- Across five years, Gross Margin topped out at 96.44% in Q4 2022 and bottomed at 3.17% in Q1 2025.
- The 5-year median for Gross Margin is 83.35% (2022), against an average of 74.43%.
- Across the five-year window, Gross Margin tumbled 9095 bps in 2025 and jumped 8829 bps in 2026, its largest moves.
- Year by year, Gross Margin stood at 96.44% in 2022, then slipped by 1 bps to 95.9% in 2023, then slipped by 17 bps to 79.91% in 2024, then plunged by 88 bps to 9.98% in 2025, then surged by 752 bps to 85.12% in 2026.
- Per Business Quant, the three latest SRPT Gross Margin figures stand at 85.12% (Q1 2026), 9.98% (Q4 2025), and 62.25% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Sarepta Therapeutics | 1.69 Bn | 1.28 Bn | 622.04 Mn | 85.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85.12% |
| Dec 31, 2025 | 9.98% |
| Sep 30, 2025 | 62.25% |
| Jun 30, 2025 | 75.04% |
| Mar 31, 2025 | -3.17% |
| Dec 31, 2024 | 79.91% |
| Sep 30, 2024 | 80.37% |
| Jun 30, 2024 | 87.73% |
| Mar 31, 2024 | 87.77% |
| Dec 31, 2023 | 95.90% |
| Sep 30, 2023 | 88.03% |
| Jun 30, 2023 | 86.94% |
| Mar 31, 2023 | 84.87% |
| Dec 31, 2022 | 96.44% |
| Sep 30, 2022 | 82.65% |
| Jun 30, 2022 | 82.11% |
| Mar 31, 2022 | 83.35% |
| Dec 31, 2021 | 82.24% |
| Sep 30, 2021 | -4.22% |
| Jun 30, 2021 | 88.11% |